Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Aberrant DNA methylation and overexpression of NR0B1 are prognostic biomarkers in KEAP1-mutant lung adenocarcinomas.

Discover oncology·2025

Same author

Construction and validation of a novel prognostic model with palmitoylation-related genes for glioblastoma.

Translational cancer research·2024

Same author

Influencing factors of intrapartum fever after epidural labor analgesia.

Revista da Associacao Medica Brasileira (1992)·2024

Same author

Dysfunction of Nrf2-regulated cellular defence system and JNK activation induced by high dose of fly Ash particles are associated with pulmonary injury in mouse lungs.

Ecotoxicology and environmental safety·2024

Same author

NRF2 has a splicing regulatory function involving the survival of motor neuron (SMN) in non-small cell lung cancer.

Oncogene·2023

Same author

The nuclear transportation of PD-L1 and the function in tumor immunity and progression.

Cancer immunology, immunotherapy : CII·2022

Search research articles

Related Experiment Video

Updated: Jun 20, 2026

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

Bexarotene: a promising anticancer agent.

Liyan Qu¹, Xiuwen Tang

¹Department of Biochemistry and Genetics, School of Medicine, Zhejiang University, Hangzhou, People's Republic of China.

Cancer Chemotherapy and Pharmacology

|September 25, 2009

Summary

This summary is machine-generated.

Bexarotene, a selective retinoid X receptor (RXR) agonist, shows promise as a cancer chemopreventive agent. It effectively blocks cell cycle progression, induces apoptosis, and inhibits cancer spread, offering a new therapeutic avenue.

Related Experiment Videos

Last Updated: Jun 20, 2026

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

Area of Science:

Biochemistry
Molecular Biology
Oncology

Background:

Retinoids, vitamin A derivatives, are crucial for embryonic and adult cell functions.
Biologic effects of retinoids are mediated by retinoid acid receptors (RARs) and retinoid X receptors (RXRs).

Purpose of the Study:

To investigate the chemopreventive potential of bexarotene, a selective RXR agonist.
To elucidate the mechanisms by which bexarotene impacts cancer cell behavior.

Main Methods:

The study focuses on the molecular mechanisms of bexarotene action.
Analysis of bexarotene's effects on cell cycle progression, apoptosis, and angiogenesis.

Main Results:

Bexarotene effectively blocks cancer cell cycle progression.
It induces apoptosis (programmed cell death) in cancer cells.
Bexarotene inhibits angiogenesis and metastasis, and prevents multidrug resistance.

Conclusions:

Bexarotene demonstrates significant potential as a chemopreventive agent against cancer.
Its multifaceted action on cancer cell biology supports its therapeutic promise.